Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | THPO | P40225 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23933730 | 1.00 | ALDH1A1 (0.39) | ALDH1A1PDE4AKDM4EMAPTTHRB | |
| SCHEMBL1311637 | 1.00 | ALDH1A1 (0.39) | ALDH1A1PDE4AKDM4EMAPTTHRB | |
| SCHEMBL7156151 | 1.00 | ALDH1A1 (0.39) | ALDH1A1PDE4AKDM4EMAPTTHRB | |
| SCHEMBL15547653 | 1.00 | ALDH1A1 (0.39) | ALDH1A1PDE4AKDM4EMAPTTHRB | |
| SCHEMBL9075213 | 1.00 | ALDH1A1 (0.39) | ALDH1A1PDE4AKDM4EMAPTTHRB | |
| SCHEMBL28992556 | 0.94 | ALDH1A1 (0.37) | ALDH1A1PDE4AKDM4EMAPTTHRB | |
| SCHEMBL7153508 | 0.85 | ALDH1A1 (0.34) | ALDH1A1PDE4AKDM4EMAPTTHRB | |
| SCHEMBL3513773 | 0.85 | ALDH1A1 (0.34) | ALDH1A1PDE4AKDM4EMAPTTHRB | |
| SCHEMBL3344516 | 0.85 | ALDH1A1 (0.34) | ALDH1A1PDE4AKDM4EMAPTTHRB | |
| SCHEMBL28900822 | 0.85 | ALDH1A1 (0.34) | ALDH1A1PDE4AKDM4EMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150238596-A1 | BIOCONJUGATES COMPRISING MODIFIED ANTIGENS AND USES THEREOF | GLYCOVAXYN AG (CH) | 2015-08-27 | — | — | US | disclosed |
| EP-2892566-A1 | BIOCONJUGATES COMPRISING MODIFIED ANTIGENS AND USES THEREOF | Glycovaxyn AG (CH) | 2015-07-15 | — | — | EP | disclosed |
| WO-2014037585-A1 | BIOCONJUGATES COMPRISING MODIFIED ANTIGENS AND USES THEREOF | GLYCOVAXYN AG (CH) | 2014-03-13 | — | — | WO | disclosed |
| EP-1509607-B1 | IMMUNOGENIC SEQUENCES | SECR DEFENCE (GB) | 2013-02-20 | — | — | EP | disclosed |
| US-8198430-B2 | Immunogenic sequences | THE SECRETARY OF STATE FOR DEFENCE (GB) | 2012-06-12 | — | — | US | disclosed |
| US-20100080828-A1 | IMMUNOGENIC SEQUENCES | THE SECRETARY OF STATE OF DEFENCE (GB) | 2010-04-01 | — | — | US | disclosed |
| US-20070128225-A1 | Immunogenic sequences | PRIOR JOANN L | 2007-06-07 | — | — | US | disclosed |
| US-20050112141-A1 | Compositions and methods for treatment of neoplastic disease | GRANDVIEW, LLC | 2005-05-26 | — | — | US | disclosed |
| EP-1509607-A1 | IMMUNOGENIC SEQUENCES | The Secretary of State for Defence (GB) | 2005-03-02 | — | — | EP | disclosed |
| US-20040214783-A1 | conjugates, fusion proteins or naked nucleic acids of superantigen (SAg) which produce an anti-tumor responses in transfected host cells (tumor cells, accessory cells or lymphocytes); cancer treatment | TERMAN DAVID S (US) | 2004-10-28 | — | — | US | disclosed |
| WO-2003102191-A1 | IMMUNOGENIC SEQUENCES | THE SECRETARY OF STATE FOR DEFENCE (GB) | 2003-12-11 | — | — | WO | disclosed |
| US-20030157113-A1 | Mammalian cell which inhibits cellular activation by receptors specific for lipid-based tumor associatiated antigens; anticancer agents | TERMAN DAVID S (US) | 2003-08-21 | — | — | US | disclosed |
| US-20020177551-A1 | Compositions and methods for treatment of neoplastic disease | TERMAN DAVID S (US) | 2002-11-28 | — | — | US | disclosed |
| US-4818817-A | DEMULSIFICATION | PETROLEUM FERMENTATIONS N.V. (AN) | 1989-04-04 | — | — | US | disclosed |
| US-4704360-A | DEMULSIFIERS | PETROLEUM FERMENTATIONS (AN) | 1987-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150238596-A1 | BIOCONJUGATES COMPRISING MODIFIED ANTIGENS AND USES THEREOF | O60361, EEA1, SELE | ALDH1A1 2570/4885PDE4A 4541/4885KDM4E 4624/4885 |
| US-20040214783-A1 | conjugates, fusion proteins or naked nucleic acids of superantigen (SAg) which produce an anti-tumor responses in transfected host cells (tumor cells, accessory cells or lymphocytes); cancer treatment | GZMB, SON, SRRT | ALDH1A1 4875/4885PDE4A 4182/4885KDM4E 4410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.